TEMPO.CO, Bandung - Vaccine Manufacturer Bio Farma will launch and sell biosimilar medicine to treat breast cancer at much lower cost compared to the current market price.
Bio Farma senior researcher Erman Tritama inBandung said on Sunday (19/3) revealed that Bio Farma research and development team has produced biosimilar medicine ready to launch and sell to market in 2019.
Erman added that Bio Farma plans to sell biosimilar medicine (biological product derived from living substances namely tissues, cells, DNA, and protein) at a price lower than 50 percent of the price produced by European company, Roche, which costs 25 milion rupiahs in one dose.
"Breast cancer biosimilar is patended for 20 years, and the patent will be over in 2019," Erman said. The patent, Erman added, has caused medicine monopoly and a very high price.